Premium
Changes in prescribing habits for the treatment of metastatic renal clear cell carcinoma ( mRCC ) in Australia
Author(s) -
Balasubramanian Adithya,
Qu Liang,
Weickhardt Andrew,
Bolton Damien,
Perera Marlon
Publication year - 2021
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.15419
Subject(s) - medicine , sunitinib , renal cell carcinoma , schedule , expanded access , oncology , intensive care medicine , family medicine , computer science , operating system
The availability of efficacious systemic therapies for metastatic clear cell renal cell carcinoma has heralded improved survival for Australians. The Pharmaceutical Benefits Schedule registry was interrogated to assess nation‐wide prescribing patterns. Sunitinib remained the most commonly prescribed agent. Prescribing rates were significantly lower in Northern Territory than in other states, raising questions of disparities in access to care.